Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 239

1.

Brain monoamine oxidase B and A in human parkinsonian dopamine deficiency disorders.

Tong J, Rathitharan G, Meyer JH, Furukawa Y, Ang LC, Boileau I, Guttman M, Hornykiewicz O, Kish SJ.

Brain. 2017 Sep 1;140(9):2460-2474. doi: 10.1093/brain/awx172.

PMID:
29050386
2.

Dopamine and noradrenaline, but not serotonin, in the human claustrum are greatly reduced in patients with Parkinson's disease: possible functional implications.

Sitte HH, Pifl C, Rajput AH, Hörtnagl H, Tong J, Lloyd GK, Kish SJ, Hornykiewicz O.

Eur J Neurosci. 2017 May;45(10):1356. doi: 10.1111/ejn.13573. No abstract available.

PMID:
28523903
3.

L-DOPA.

Hornykiewicz O.

J Parkinsons Dis. 2017;7(s1):S3-S10. doi: 10.3233/JPD-179004. Review. No abstract available.

4.

Dopamine and noradrenaline, but not serotonin, in the human claustrum are greatly reduced in patients with Parkinson's disease: possible functional implications.

Sitte HH, Pifl C, Rajput AH, Hörtnagl H, Tong J, Lloyd GK, Kish SJ, Hornykiewicz O.

Eur J Neurosci. 2017 Jan;45(1):192-197. doi: 10.1111/ejn.13435. Epub 2016 Nov 11. Erratum in: Eur J Neurosci. 2017 May;45(10 ):1356.

PMID:
27741357
5.

A marked contrast between serotonergic and dopaminergic changes in dopa-responsive dystonia.

Furukawa Y, Rajput AH, Tong J, Tomizawa Y, Hornykiewicz O, Kish SJ.

Neurology. 2016 Sep 6;87(10):1060-1. doi: 10.1212/WNL.0000000000003065. Epub 2016 Aug 3. No abstract available.

6.

Low levels of astroglial markers in Parkinson's disease: relationship to α-synuclein accumulation.

Tong J, Ang LC, Williams B, Furukawa Y, Fitzmaurice P, Guttman M, Boileau I, Hornykiewicz O, Kish SJ.

Neurobiol Dis. 2015 Oct;82:243-253. doi: 10.1016/j.nbd.2015.06.010. Epub 2015 Jun 21.

7.

50 years of levodopa.

Hornykiewicz O.

Mov Disord. 2015 Jun;30(7):1008. doi: 10.1002/mds.26240. Epub 2015 May 21. No abstract available.

PMID:
25999218
8.

The profile of mephedrone on human monoamine transporters differs from 3,4-methylenedioxymethamphetamine primarily by lower potency at the vesicular monoamine transporter.

Pifl C, Reither H, Hornykiewicz O.

Eur J Pharmacol. 2015 May 15;755:119-26. doi: 10.1016/j.ejphar.2015.03.004. Epub 2015 Mar 11.

PMID:
25771452
9.

Is Parkinson's disease a vesicular dopamine storage disorder? Evidence from a study in isolated synaptic vesicles of human and nonhuman primate striatum.

Pifl C, Rajput A, Reither H, Blesa J, Cavada C, Obeso JA, Rajput AH, Hornykiewicz O.

J Neurosci. 2014 Jun 11;34(24):8210-8. doi: 10.1523/JNEUROSCI.5456-13.2014. Erratum in: J Neurosci. 2015 Nov 25;35(47):15767.

10.

Reduced noradrenaline, but not dopamine and serotonin in motor thalamus of the MPTP primate: relation to severity of parkinsonism.

Pifl C, Hornykiewicz O, Blesa J, Adánez R, Cavada C, Obeso JA.

J Neurochem. 2013 Jun;125(5):657-62. doi: 10.1111/jnc.12162. Epub 2013 Feb 13.

11.

Thalamic noradrenaline in Parkinson's disease: deficits suggest role in motor and non-motor symptoms.

Pifl C, Kish SJ, Hornykiewicz O.

Mov Disord. 2012 Nov;27(13):1618-24. doi: 10.1002/mds.25109. Epub 2012 Oct 4.

12.

The nigrostriatal system in the presymptomatic and symptomatic stages in the MPTP monkey model: a PET, histological and biochemical study.

Blesa J, Pifl C, Sánchez-González MA, Juri C, García-Cabezas MA, Adánez R, Iglesias E, Collantes M, Peñuelas I, Sánchez-Hernández JJ, Rodríguez-Oroz MC, Avendaño C, Hornykiewicz O, Cavada C, Obeso JA.

Neurobiol Dis. 2012 Oct;48(1):79-91. doi: 10.1016/j.nbd.2012.05.018. Epub 2012 Jun 5.

PMID:
22677034
13.

Chronic exposure to manganese decreases striatal dopamine turnover in human alpha-synuclein transgenic mice.

Peneder TM, Scholze P, Berger ML, Reither H, Heinze G, Bertl J, Bauer J, Richfield EK, Hornykiewicz O, Pifl C.

Neuroscience. 2011 Apr 28;180:280-92. doi: 10.1016/j.neuroscience.2011.02.017. Epub 2011 Feb 16.

PMID:
21333719
14.

A brief history of levodopa.

Hornykiewicz O.

J Neurol. 2010 Nov;257(Suppl 2):S249-52. doi: 10.1007/s00415-010-5741-y. Review.

PMID:
21080185
15.

Heterogeneous intrastriatal pattern of proteins regulating axon growth in normal adult human brain.

Tong J, Furukawa Y, Sherwin A, Hornykiewicz O, Kish SJ.

Neurobiol Dis. 2011 Feb;41(2):458-68. doi: 10.1016/j.nbd.2010.10.017. Epub 2010 Oct 26.

16.

Metabotropic glutamate receptor type 5 in levodopa-induced motor complications.

Ouattara B, Grégoire L, Morissette M, Gasparini F, Vranesic I, Bilbe G, Johns DR, Rajput A, Hornykiewicz O, Rajput AH, Gomez-Mancilla B, Di Paolo T.

Neurobiol Aging. 2011 Jul;32(7):1286-95. doi: 10.1016/j.neurobiolaging.2009.07.014. Epub 2009 Dec 29.

PMID:
20036444
17.

Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation.

Tong J, Wong H, Guttman M, Ang LC, Forno LS, Shimadzu M, Rajput AH, Muenter MD, Kish SJ, Hornykiewicz O, Furukawa Y.

Brain. 2010 Jan;133(Pt 1):172-88. doi: 10.1093/brain/awp282. Epub 2009 Nov 10.

PMID:
19903734
18.

Metabotropic glutamate receptor II in the brains of Parkinsonian patients.

Samadi P, Rajput A, Calon F, Grégoire L, Hornykiewicz O, Rajput AH, Di Paolo T.

J Neuropathol Exp Neurol. 2009 Apr;68(4):374-82. doi: 10.1097/NEN.0b013e31819cabe4.

PMID:
19287314
19.

Decreased binding of the D3 dopamine receptor-preferring ligand [11C]-(+)-PHNO in drug-naive Parkinson's disease.

Boileau I, Guttman M, Rusjan P, Adams JR, Houle S, Tong J, Hornykiewicz O, Furukawa Y, Wilson AA, Kapur S, Kish SJ.

Brain. 2009 May;132(Pt 5):1366-75. doi: 10.1093/brain/awn337. Epub 2009 Jan 19.

PMID:
19153147
20.

The effect of l-3,4-dihydroxyphenylalanine (=DOPA) on akinesia in parkinsonism.

Birkmayer W, Hornykiewicz O.

Parkinsonism Relat Disord. 1998 Aug;4(2):59-60. No abstract available.

PMID:
18591089
21.

Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system.

Ehringer H, Hornykiewicz O.

Parkinsonism Relat Disord. 1998 Aug;4(2):53-7. No abstract available.

PMID:
18591088
22.

Basic research on dopamine in Parkinson's disease and the discovery of the nigrostriatal dopamine pathway: the view of an eyewitness.

Hornykiewicz O.

Neurodegener Dis. 2008;5(3-4):114-7. doi: 10.1159/000113678. Epub 2008 Mar 6.

PMID:
18322366
23.

Globus pallidus dopamine and Parkinson motor subtypes: clinical and brain biochemical correlation.

Rajput AH, Sitte HH, Rajput A, Fenton ME, Pifl C, Hornykiewicz O.

Neurology. 2008 Apr 15;70(16 Pt 2):1403-10. doi: 10.1212/01.wnl.0000285082.18969.3a. Epub 2008 Jan 2.

PMID:
18172064
24.

Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease.

Kish SJ, Tong J, Hornykiewicz O, Rajput A, Chang LJ, Guttman M, Furukawa Y.

Brain. 2008 Jan;131(Pt 1):120-31. Epub 2007 Oct 22.

PMID:
17956909
25.

Marked dissociation between high noradrenaline versus low noradrenaline transporter levels in human nucleus accumbens.

Tong J, Hornykiewicz O, Furukawa Y, Kish SJ.

J Neurochem. 2007 Sep;102(5):1691-1702. doi: 10.1111/j.1471-4159.2007.04636.x. Epub 2007 May 4.

27.

The discovery of dopamine deficiency in the parkinsonian brain.

Hornykiewicz O.

J Neural Transm Suppl. 2006;(70):9-15. Review.

PMID:
17017502
28.

Dopamine turnover is upregulated in the caudate/putamen of asymptomatic MPTP-treated rhesus monkeys.

Pifl C, Hornykiewicz O.

Neurochem Int. 2006 Oct;49(5):519-24. Epub 2006 May 15.

PMID:
16698121
29.

Identification of a noradrenaline-rich subdivision of the human nucleus accumbens.

Tong J, Hornykiewicz O, Kish SJ.

J Neurochem. 2006 Jan;96(2):349-54. Epub 2005 Nov 29.

30.

Dopamine inhibits cell growth and cell cycle by blocking ribonucleotide reductase.

Woldman I, Reither H, Kattinger A, Hornykiewicz O, Pifl C.

Neuropharmacology. 2005 Mar;48(4):525-37. Epub 2005 Jan 25.

PMID:
15755480
31.

Levodopa in the treatment of Parkinson's disease: current controversies.

Olanow CW, Agid Y, Mizuno Y, Albanese A, Bonuccelli U, Damier P, De Yebenes J, Gershanik O, Guttman M, Grandas F, Hallett M, Hornykiewicz O, Jenner P, Katzenschlager R, Langston WJ, LeWitt P, Melamed E, Mena MA, Michel PP, Mytilineou C, Obeso JA, Poewe W, Quinn N, Raisman-Vozari R, Rajput AH, Rascol O, Sampaio C, Stocchi F.

Mov Disord. 2004 Sep;19(9):997-1005. Review. Erratum in: Mov Disord. 2005 May;20(5):645. Bonucelli, U [corrected to Bonuccelli, Ubaldo].

PMID:
15372588
32.

Proposal for a noradrenaline hypothesis of schizophrenia.

Yamamoto K, Hornykiewicz O.

Prog Neuropsychopharmacol Biol Psychiatry. 2004 Aug;28(5):913-22. Review.

PMID:
15363614
33.

The role of iron and copper molecules in the neuronal vulnerability of locus coeruleus and substantia nigra during aging.

Zecca L, Stroppolo A, Gatti A, Tampellini D, Toscani M, Gallorini M, Giaveri G, Arosio P, Santambrogio P, Fariello RG, Karatekin E, Kleinman MH, Turro N, Hornykiewicz O, Zucca FA.

Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9843-8. Epub 2004 Jun 21.

34.

Human brain dopamine metabolism in levodopa-induced dyskinesia and wearing-off.

Rajput AH, Fenton ME, Di Paolo T, Sitte H, Pifl C, Hornykiewicz O.

Parkinsonism Relat Disord. 2004 Jun;10(4):221-6.

PMID:
15120096
35.

Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias.

Calon F, Dridi M, Hornykiewicz O, Bédard PJ, Rajput AH, Di Paolo T.

Brain. 2004 May;127(Pt 5):1075-84. Epub 2004 Mar 19.

PMID:
15033896
36.

alpha-Synuclein selectively increases manganese-induced viability loss in SK-N-MC neuroblastoma cells expressing the human dopamine transporter.

Pifl C, Khorchide M, Kattinger A, Reither H, Hardy J, Hornykiewicz O.

Neurosci Lett. 2004 Jan 2;354(1):34-7.

PMID:
14698476
37.

Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease.

Calon F, Rajput AH, Hornykiewicz O, Bédard PJ, Di Paolo T.

Neurobiol Dis. 2003 Dec;14(3):404-16.

PMID:
14678757
38.

Marked disparity between age-related changes in dopamine and other presynaptic dopaminergic markers in human striatum.

Haycock JW, Becker L, Ang L, Furukawa Y, Hornykiewicz O, Kish SJ.

J Neurochem. 2003 Nov;87(3):574-85.

39.

Changes of GABA receptors and dopamine turnover in the postmortem brains of parkinsonians with levodopa-induced motor complications.

Calon F, Morissette M, Rajput AH, Hornykiewicz O, Bédard PJ, Di Paolo T.

Mov Disord. 2003 Mar;18(3):241-53.

PMID:
12621627
40.
41.

Cellular effects of dopamine--beyond oxidative mechanisms.

Pifl C, Kattinger A, Reither H, Hornykiewicz O.

Parkinsonism Relat Disord. 2002 Sep;8(6):433-7.

PMID:
12217632
42.

Dopamine miracle: from brain homogenate to dopamine replacement.

Hornykiewicz O.

Mov Disord. 2002 May;17(3):501-8. No abstract available.

PMID:
12112197
43.

Clinical-pathological study of levodopa complications.

Rajput AH, Fenton ME, Birdi S, Macaulay R, George D, Rozdilsky B, Ang LC, Senthilselvan A, Hornykiewicz O.

Mov Disord. 2002 Mar;17(2):289-96.

PMID:
11921114
44.

Increase of preproenkephalin mRNA levels in the putamen of Parkinson disease patients with levodopa-induced dyskinesias.

Calon F, Birdi S, Rajput AH, Hornykiewicz O, Bédard PJ, Di Paolo T.

J Neuropathol Exp Neurol. 2002 Feb;61(2):186-96.

PMID:
11853020
45.

The effect of l-3,4-dihydroxyphenylalanine (= DOPA) on akinesia in parkinsonism. 1961.

Birkmayer W, Hornykiewicz O.

Wien Klin Wochenschr. 2001 Nov 15;113(22):851-4. English, German. No abstract available.

PMID:
11763859
46.

How L-DOPA was discovered as a drug for Parkinson's disease 40 years ago.

Hornykiewicz O.

Wien Klin Wochenschr. 2001 Nov 15;113(22):855-62. No abstract available.

PMID:
11762121
47.

Elevated levels of DeltaFosB and RGS9 in striatum in Parkinson's disease.

Tekumalla PK, Calon F, Rahman Z, Birdi S, Rajput AH, Hornykiewicz O, Di Paolo T, Bédard PJ, Nestler EJ.

Biol Psychiatry. 2001 Nov 15;50(10):813-6.

PMID:
11720701
48.

Dopamine and Parkinson's disease. A personal view of the past, the present, and the future.

Hornykiewicz O.

Adv Neurol. 2001;86:1-11. No abstract available.

PMID:
11553966
49.

Chemical neuroanatomy of the basal ganglia--normal and in Parkinson's disease.

Hornykiewicz O.

J Chem Neuroanat. 2001 Jul;22(1-2):3-12. Review. No abstract available.

PMID:
11470551
50.

Antiproliferative action of dopamine and norepinephrine in neuroblastoma cells expressing the human dopamine transporter.

Pifl C, Zezula J, Spittler A, Kattinger A, Reither H, Caron MG, Hornykiewicz O.

FASEB J. 2001 Jul;15(9):1607-9. No abstract available.

PMID:
11427501

Supplemental Content

Loading ...
Support Center